The inflammatory myositis diagnosis market consists of various diagnostic tests and services used to identify inflammatory myositis conditions such as dermatomyositis and polymyositis. Diagnosis primarily involves physical examination, blood tests to detect elevated muscle enzyme levels, imaging tests such as MRI and biopsy of affected muscle tissue. Imaging tests help analyze muscle inflammation and damage while biopsy aids in distinguishing between various myositis subtypes. Biomarker testing is also gaining significance where autoantibodies are detected in patient serum to identify specific myositis phenotypes.
The inflammatory myositis diagnosis market is estimated to be valued at USD 608 million in 2024 and is expected to reach USD 900 million by 2031, growing at a compound annual growth rate (CAGR) of 5.8% from 2024 to 2031.
Key players operating in the inflammatory myositis diagnosis are Quest Diagnostics, Euroimmun US, Inova Diagnostics, Myositis Association and Celiac Disease Foundation.
There is growing demand for advanced diagnostic technologies owing to increasing myositis disease prevalence worldwide and lack of early specific symptoms. Biomarker testing is being widely adopted as it detects myositis before muscle damage occurs and patients respond better to early treatment intervention.
Technological advancements are revolutionizing Inflammatory Myositis Diagnosis Market with new autoantibody biomarkers being identified annually. Laboratory developed tests are commercially launched that accurately profile multiple autoantibodies on a single platform for comprehensive myositis characterization.
Market Trends
- Combination biomarker panels are gaining popularity as they can identify myositis subtypes and predict disease progression more precisely. Multiplex testing of autoantibodies is the future.
- Non-invasive diagnostic methods are being explored like ultrasound molecular imaging to visualize muscle inflammation in real time and aid early treatment monitoring without repeated muscle biopsies.
Market Opportunities
- Emerging markets present lucrative opportunities due to improving access to healthcare facilities and increasing medical expenditures.
- Adoption of point-of-care testing holds promise for convenient biomarker screening near patient location in hospitals as well as physicians offices. This can facilitate faster diagnosis and treatment management.
Impact of COVID-19 on Inflammatory Myositis Diagnosis Market Growth
The COVID-19 pandemic has significantly impacted the growth of the inflammatory myositis diagnosis market. During the initial lockdown phase globally, both patients and healthcare professionals avoided in-person visits and consultations as much as possible due to the risk of virus transmission. This led to postponing of several non-emergency diagnosis procedures in 2020 as priority was given to handle critical COVID-19 cases. The utilization of various diagnostic tests like MRI, blood tests, muscle biopsy etc declined sharply, hampering the market expansion.
However, with lifting of lockdowns and normalization of operations, the demand is recovering gradually post 2020. The diagnostic procedures and testing volumes are increasing again as patients are now more comfortable visiting hospitals and clinics while maintaining proper safety protocols. Telemedicine and virtual consultations have also picked up, helping doctors to remotely review reports and prescribe additional tests if needed.
In terms of geographical revenue concentration, North America dominated the global inflammatory myositis diagnosis market in the pre-COVID era mainly due to high awareness levels, availability of advanced healthcare facilities and presence of major market players. The United States accounted for the largest share within the region. However, Asia Pacific is projected to experience the fastest growth during the forecast period owing to rising disease prevalence, growing medical tourism and increasing healthcare expenditures in developing countries like India and China.
European region holds the second position interms of market value currently. Countries with well-established healthcare systems like Germany, United Kingdom and France are the major revenue generators. But Latin American countries are believed to offer new growth opportunities in the coming years supported by improving economic conditions and healthcare reforms. Overall, the long-term outlook remains positive with increasing adoption of novel diagnostic methods worldwide.
Get more insights on: Inflammatory Myositis Diagnosis Market
Get this Report in Japanese Language: 炎症性筋炎診断市場
Get this Report in Korean Language: 염증성 근염 진단 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)